Some drugs used for T2D, such as gliclazide (G), have beneficial extrapancreatic effects that include antiplatelet, antiradical and antioxidants effects, so some T2D patients continue to use gliclazide (G) after the loss of insulin secretion since it provides better glycaemic control than insulin alone [4–6]. This evidence concerns the gene INS and type 2 diabetes mellitus.